Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Spero Therapeutics Inc (SPRO)

59 + Investors. Track Smart Money conviction in SPRO. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +11
Streak
1Q ▲
Buyers last Q
66%

Smart Money Signals — SPRO

Based on 60 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added SPRO than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
60 hedge funds hold SPRO right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +40% more funds vs a year ago

fund count last 6Q
+17 new funds entered over the past year (+40% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 66% buying

40 buying21 selling
Last quarter: 40 funds were net buyers (23 opened a brand new position + 17 added to an existing one). Only 21 were sellers (9 trimmed + 12 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+16 vs last Q)

new funds entering per quarter
Funds opening a new SPRO position: 15 → 14 → 7 → 23. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

43% of holders stayed for 2+ years

■ 43% conviction (2yr+) ■ 32% medium ■ 25% new
26 out of 60 hedge funds have held SPRO for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
➡️

Steady discovery — ~23 new funds/quarter

15 → 15 → 14 → 7 → 23 new funds/Q
New funds entering each quarter: 15 → 14 → 7 → 23. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Veteran-anchored — 66% veterans vs 28% newcomers

■ 66% veterans ■ 6% 1-2yr ■ 28% new
Entry-cohort mix of 64 holders: 42 (66%) are 2+ year veterans, 4 entered 1–2 years ago, and 18 (28%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
📋

Smaller funds dominant — 15% AUM from top-100

15% from top-100 AUM funds
21 of 59 holders rank in the top 100 by AUM, but together hold only 15% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
3.8
out of 10
Low Exit Risk
Exit risk score 3.8/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — SPRO

In 2026 Q2, 40 hedge funds were net buyers of SPRO (23 opened a new position, 17 added to an existing one), while 21 reduced or exited (9 trimmed, 12 sold completely) — a 66% buyer ratio, indicating clear institutional accumulation. Net fund flow last quarter: +11 funds (more new holders than closures). Total institutional holders: 60.

Hedge Fund Ownership: SPRO

How many hedge funds hold SPRO — quarterly history vs. share price
Quarterly hedge fund ownership of SPRO vs. share price

Market Analysis: SPRO

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: SPRO

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Spero Therapeutics Inc (SPRO) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much SPRO has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 57d ago
SPRO
-45.0%
XLV
+10.7%

SPRO outperformed XLV by -55.7% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 12d ago
SPRO
-1.2%
XLV
+5.0%

Since the filing became public, SPRO outperformed XLV by -6.2% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

6 top-rated funds 2 high-conviction
Consensus
3.7
/ 10
breadth
×
Elite
1.4
/ 10
conviction
Hedge Fund Positioning: SPRO
59 + Investors

Track Smart Money conviction in SPRO. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 59 49 20.41%
13F Shares 22M 21M 2.89%
Total Value $47M $48M -2.68%
New Positions 23 7 +16
Increased Positions 16 12 +4
Closed Positions 12 14 -2
Reduced Positions 7 10 -3
Total Calls 2 2 -
Total Puts 3 3 -
PUT/CALL Ratio 1.5 1.5 Bearish

Statistics: SPRO

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

59 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in SPRO. Verified SEC 13F-HR filings.

QUARTER:
Top 25 SPRO holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 GSK plc 3.37% 9,190,606 $20.3M
2 Pfizer Inc 3.13% 2,362,348 $5.3M
3 Verdad Advisers, LP 0.11% 51,335 $113K
4 Ionic Capital Management LLC 0.03% 102,698 $227K
5 DLK Investment Management, LLC 0.02% 31,355 $41K
6 Shay Capital LLC 0.01% 72,391 $160K
7 Three Seasons Wealth, LLC 0.01% 30,000 $66K
8 Bridgeway Capital Management, LLC 0.00% 114,800 $254K
9 Renaissance Technologies LLC 0.00% 947,904 $2.1M
10 Capital Asset Advisory Services LLC 0.00% 32,548 $72K
11 Two Sigma Securities, LLC 0.00% 10,576 $23K
12 Alphabet Inc. 0.00% 889,979 $2.0M
13 XTX Topco Ltd 0.00% 50,536 $112K
14 Axxcess Wealth Management, LLC 0.00% 32,548 $72K
15 Global Retirement Partners, LLC 0.00% 25,000 $55K
16 Susquehanna Fundamental Investments, LLC 0.00% 16,095 $36K
17 Susquehanna Portfolio Strategies, LLC 0.00% 17,628 $39K
18 Federation des caisses Desjardins du Quebec 0.00% 91,900 $202K
19 Two Sigma Investments, LP 0.00% 382,814 $846K
20 Oppenheimer & Co Inc 0.00% 22,850 $50K
21 Arrowstreet Capital, Limited Partnership 0.00% 332,970 $736K
22 Raymond James Financial Inc 0.00% 521,705 $1.2M
23 Point72 Asset Management, L.P. 0.00% 104,377 $231K
24 Vanguard Fiduciary Trust Co 0.00% 287,648 $636K
25 Susquehanna International Group, LLP 0.00% 759,290 $1.7M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Spero Therapeutics Inc (SPRO)

What does the Smart Money Trend signal show for SPRO?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added SPRO than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for SPRO?

More buyers than sellers — 66% buying: Last quarter: 40 funds were net buyers (23 opened a brand new position + 17 added to an existing one). Only 21 were sellers (9 trimmed + 12 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for SPRO holders?

Smaller funds dominant — 15% AUM from top-100: 21 of 59 holders rank in the top 100 by AUM, but together hold only 15% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held SPRO?

43% of holders stayed for 2+ years: 26 out of 60 hedge funds have held SPRO for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Spero Therapeutics Inc (SPRO) following the 2026 Q2 hedge fund 13F filings?

As of today, SPRO has moved -1.2% since the 2026 Q2 13F filing date (August 14, 2026), compared to +5.0% for the XLV sector ETF — an outperformance of -6.2%. Since the quarter end (June 30, 2026), SPRO has gained -45.0% vs +10.7% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →